HBI Deals+Insights / M&A/IPOs

Polypeptide Group attracts takeover interest from private equity firms

Polypeptide Group, a listed Switzerland-based contract development and manufacturing organisation (CDMO) serving pharmaceutical and biotech companies, has attracted takeover interest from private equity investors. The company specialises in peptide-based active pharmaceutical ingredients (APIs) and operates manufacturing sites across the United States, Europe, and India.